Cerulean is focused on significantly improving the efficacy and safety profile of cancer drugs that employ advances in nanotechnology. The company completed its IPO in 2014.
Using the science of nanotechnology, Cerulean is developing a suite of potent new cancer drugs that selectively target tumors, burrowing their way into cancer cells while leaving healthy cells unaffected. Clinical results indicate the drugs have the potential to be effective across numerous cancer types, while improving both safety and quality-of-life for patients. The company’s lead drug is currently being evaluated in Phase II clinical trials. The drug platform has also shown promise in delivering gene therapy to cancer cells. The company completed its IPO in 2014.